Managing clinical conditions: Fuch’s dystrophy

Article

Paul Karpecki, OD, FAAO, and Jill Autry, OD, RPh, shared Fuch's dystrophy management pearls with attendees at the American Optometric Association’s Optometry’s Meeting.

 

Philadelphia-Paul Karpecki, OD, FAAO, and Jill Autry, OD, RPh, shared clinical management pearls with attendees at the American Optometric Association’s Optometry’s Meeting.

In the past three years, more ODs bought specular microscopes than ophthalmologists, says Dr. Karpecki. Some 78 percent of ODs have pachymeters in the office as well. These instruments allow ODs to help manage certain clinical conditions.

Consider these four clinical stages of Fuch’s dystrophy before referring a patient with this condition.

• Guttata

• Stroma edema with decreased vision, worse in the morning

• Epithelium edema, including pain with ruptured bullae and further decrease in vision

• Corneal scarring

"If the epithelium can't pump, that's when we have problems," says Dr. Autry.

Says Dr. Karpecki: It’s time to start educating the patient about future surgical options, such as transplant, with these clinical signs:

• Morning blur that lasts a significant amount of time, such as >30 minutes

• Pachymeters over 600 µm in a patient who previously had normal (~550 µm) corneal thickness

• Specular microscopy signs

• First cataract surgery resulted in endothelial decompensation

Treatment for Fuch’s dystrophy includes:

• Observation

• Muro 128 5% solution/ung; a generic is available at half the price of brand; order online for better pricing

• FreshKote

110 mm Hg oncotic pressure pull

More comfortable daytime drop

• Lowering IOP may reduce stromal and epithelial edema

• Avoid carbonic anhyrase inhibor (CAI) medications because will further impede pumping action

• Bandage contact lens pm

Dr. Autry suggested trying a brand name medication if the results are acceptable. “If you're not hitting what you expect with a generic medication, try something else,” she says. “The eye is so good at keeping things off of it, even a small change in pH could make a difference.”

An attendee asked Drs. Autry and Karpecki if a scleral lens would be a good option for Fuch’s patient. Good question, says Dr. Karpecki. “Some people believe the one contraindication to a scleral is a compromised cornea. With newer lenses, it may not be the case. It's still a debatable question.”ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
© 2025 MJH Life Sciences

All rights reserved.